AstraZeneca says AZD0780 demonstrates significant LDL-C reduction in trial
AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...
AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial
AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 ...
The Pharma Letter6d
AstraZeneca’s AZD0780 shows ‘potential to be a game changer’
Positive results from the PURSUIT Phase IIb trial of AstraZeneca’s AZD0780 have shown a statistically significant low-density ...
MyChesCo on MSN1d
AstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical Trial
New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...
Pharmabiz6d
AstraZeneca’s AZD0780, a novel oral PCSK9 inhibitor, demonstrates significant LDL cholesterol reduction in PURSUIT phase IIb trial
AstraZeneca’s AZD0780, a novel oral PCSK9 inhibitor, demonstrates significant LDL cholesterol reduction in PURSUIT phase IIb trial: Cambridge, UK Wednesday, April 2, 2025, 11:00 ...
Clinical Trials Arena6d
ACC 2025: AZD0780 shows significant LDL-C reduction in PURSUIT Phase IIb trial
AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...
Fierce Biotech7d
AstraZeneca's oral PCSK9 inhibitor halves cholesterol in phase 2 trial
The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...
Business Insider8d
AstraZeneca says AZD0780 demonstrates significant LDL-C reduction in trial
Results from the PURSUIT Phase IIb trial for AstraZeneca’s (AZN) AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...
PipelineReview.com7d
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of ...